Stuart Orkin and Swee Lay Thein shared a Breakthrough Prize in Life Sciences for their research on genetic causes of sickle ...
A reduced-intensity bone marrow transplant regimen developed by Johns Hopkins physicians provides durable engraftment with ...
About 100,000 Americans have sickle cell disease (SCD), the most common inherited blood disorder in the US. Roughly 10% of ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...
A single one-time gene therapy could free patients with α-thalassemia, a rare and debilitating blood disorder, from the burden of lifelong transfusions. A single one-time gene therapy could free ...
Huntsville Hospital is expanding care options for patients with blood disorders, launching a new outpatient red blood cell ...
TERRIBLE. NEBRASKA ADVOCATES URGE PEOPLE TO ROLL UP THEIR SLEEVES TO SUPPORT SICKLE CELL AWARENESS MONTH. THE RED BLOOD CELL DISORDER AFFECTS 8 MILLION PEOPLE WORLDWIDE. PATIENTS REQUIRE REGULAR BLOOD ...
Casgevy’s approval changed the sickle cell disease landscape. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, the therapy showed that the disease could be tackled at its genetic root, ...
For the first time in Germany, a long-term, sustainable access agreement to a gene therapy has been established for people living with sickle cell disease and transfusion-dependent beta thalassemia,” ...
A reduced-intensity bone marrow transplant regimen developed by Johns Hopkins physicians provides durable engraftment with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results